Compare CECO & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CECO | VIR |
|---|---|---|
| Founded | 1966 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.5B |
| IPO Year | 2002 | 2019 |
| Metric | CECO | VIR |
|---|---|---|
| Price | $59.57 | $8.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $77.75 | $19.63 |
| AVG Volume (30 Days) | 647.3K | ★ 2.8M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 280.56 | 17.49 |
| EPS | ★ 1.37 | N/A |
| Revenue | N/A | ★ $68,556,000.00 |
| Revenue This Year | $24.84 | N/A |
| Revenue Next Year | $11.51 | $1,049.62 |
| P/E Ratio | $41.63 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.57 | $4.16 |
| 52 Week High | $81.72 | $10.91 |
| Indicator | CECO | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 50.96 |
| Support Level | $57.11 | $8.67 |
| Resistance Level | $63.98 | $10.29 |
| Average True Range (ATR) | 3.01 | 0.46 |
| MACD | 0.72 | -0.15 |
| Stochastic Oscillator | 49.24 | 40.57 |
CECO Environmental Corp is an industrial company, serving industrial air, industrial water, and energy transition markets. It offers various engineered and configured products and solutions, including dampers and diverters, selective catalytic reduction systems, severe-service and industrial cyclones, dust collectors, thermal oxidizers, filtration systems, wet and dry scrubbers, water treatment packages, industrial silencers, etc. These products are offered through brands like Western Airducts, WK, Wakefield Acoustics, Transcend, Verantis, and others. The company's reportable segments are: Engineered Systems, which derive maximum revenue, and Industrial Process Solutions. Geographically, it derives key revenue from the U.S., followed by the Netherlands, the UK, China, and other markets.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.